{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T01:02:24Z","timestamp":1782176544859,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:00:00Z","timestamp":1598400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:00:00Z","timestamp":1598400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008375","name":"University of Basel","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Kinder und Erwachsene mit rheumatischen Erkrankungen (RE) haben nicht nur durch ihre Grunderkrankung, sondern auch durch die vielfach notwendige immunsuppressive Therapie (IT) ein erh\u00f6htes Risiko, an bestimmten Infektionen zu erkranken. Durch die IT hat sich die Lebensqualit\u00e4t bei vielen Patienten mit RE verbessert, sodass ihr internationales Reiseverhalten dem gesunder Reisenden \u00e4hnelt. Eine Untersuchung deutet an, dass Patienten mit Immunsuppression oftmals unzureichend auf Reisen vorbereitet sind und ihr Impfschutz schlechter als bei Immungesunden ist. Da auch w\u00e4hrend und nach Reisen das Erkrankungsrisiko f\u00fcr allgemeine und reisespezifische Infektionen bei Patienten mit Immunsuppression erh\u00f6ht ist, sind reisemedizinische Beratungen bei Patienten mit RE wichtig. Hier k\u00f6nnen ein Reiser\u00fccktritt oder Reisemodifikationen und spezifischer Schutz inklusive Reiseimpfungen besprochen werden. Zu den g\u00e4ngigen Indikationsimpfungen bei Reisen z\u00e4hlen Impfungen gegen Hepatitis\u00a0A, Typhus, Tollwut, Meningokokken, FSME (Fr\u00fchsommer-Meningoenzephalitis), saisonale Influenza, Japanische Enzephalitis, Cholera, Poliomyelitis und Gelbfieber. Bei Patienten mit RE ergibt sich die Impfindikation dabei aus der m\u00f6glichen Exposition gegen\u00fcber impfpr\u00e4ventablen Infektionen, dem individuellen Reiseverhalten, der Schwere der m\u00f6glichen Infektion unter Abw\u00e4gung der Risiken, die mit der Reiseimpfung assoziiert sind. Daf\u00fcr m\u00fcssen auch der allgemeine Gesundheitszustand, die Aktivit\u00e4t und Schwere der RE und der Grad der IT beachtet werden. Allgemein gilt f\u00fcr Patienten mit RE und IT, dass auch bei Reiseimpfungen Lebendimpfstoffe kontraindiziert sind, w\u00e4hrend Totimpfstoffe verabreicht werden k\u00f6nnen. Da eine reduzierte Impfantwort m\u00f6glich ist, k\u00f6nnen Antik\u00f6rpermessungen nach der Impfserie und spezifische Impfschemata oder zus\u00e4tzliche Booster bei Patienten mit RE indiziert sein.<\/jats:p>","DOI":"10.1007\/s00393-020-00852-w","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T13:02:37Z","timestamp":1598446957000},"page":"865-872","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Reiseimpfungen bei rheumatischen Erkrankungen","Travel vaccinations in rheumatic diseases"],"prefix":"10.1007","volume":"79","author":[{"given":"T.","family":"Welzel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"W\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Heininger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,26]]},"reference":[{"key":"852_CR1","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.tmaid.2014.01.005","volume":"12","author":"HH Askling","year":"2014","unstructured":"Askling\u00a0HH, Rombo\u00a0L, Van Vollenhoven\u00a0R et al (2014) Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: a\u00a0prospective, open-label, multi-centre study. Travel Med Infect Dis 12:134\u2013142","journal-title":"Travel Med Infect Dis"},{"key":"852_CR2","volume-title":"Schweizerischer Impfplan 2020. Richtlinien und Empfehlungen","author":"Bundesamt f\u00fcr Gesundheit","year":"2020","unstructured":"Bundesamt f\u00fcr Gesundheit, Eidgen\u00f6ssische Kommission f\u00fcr Impffragen (2020) Schweizerischer Impfplan 2020. Richtlinien und Empfehlungen. Bundesamt f\u00fcr Gesundheit, Bern"},{"key":"852_CR3","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/imj.12753","volume":"45","author":"C Bialy","year":"2015","unstructured":"Bialy\u00a0C, Horne\u00a0K, Dendle\u00a0C et al (2015) International travel in the immunocompromised patient: a\u00a0cross-sectional survey of travel advice in 254 consecutive patients. Intern Med\u00a0J 45:618\u2013623","journal-title":"Intern Med J"},{"key":"852_CR4","first-page":"w14159","volume":"145","author":"S Buhler","year":"2015","unstructured":"Buhler\u00a0S, Eperon\u00a0G, Ribi\u00a0C et\u00a0al (2015) Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases. Swiss Med Wkly 145:w14159","journal-title":"Swiss Med Wkly"},{"key":"852_CR5","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/j.1708-8305.2009.00330.x","volume":"16","author":"GD Burchard","year":"2009","unstructured":"Burchard\u00a0GD, Caumes\u00a0E, Connor\u00a0BA et\u00a0al (2009) Expert opinion on vaccination of travelers against Japanese encephalitis. J\u00a0Travel Med 16:204\u2013216","journal-title":"J Travel Med"},{"key":"852_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.12.042","author":"J Burkhard","year":"2020","unstructured":"Burkhard\u00a0J, Ciurea\u00a0A, Gabay\u00a0C et al (2020) Long-term immunogenicity after yellow fever vaccination in immunosuppressed and healthy individuals. Vaccine. https:\/\/doi.org\/10.1016\/j.vaccine.2019.12.042","journal-title":"Vaccine"},{"key":"852_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taw001","author":"S Dekkiche","year":"2016","unstructured":"Dekkiche\u00a0S, De Valliere\u00a0S, D\u2019acremont\u00a0V et al (2016) Travel-related health risks in moderately and severely immunocompromised patients: a\u00a0case-control study. J\u00a0Travel Med. https:\/\/doi.org\/10.1093\/jtm\/taw001","journal-title":"J Travel Med"},{"key":"852_CR8","first-page":"1","volume-title":"Hinweise und Empfehlungen zu Reiseimpfungen","author":"Deutsche Gesellschaft f\u00fcr Tropenmedizin und Internationale Gesundheit (DTG)","year":"2017","unstructured":"Deutsche Gesellschaft f\u00fcr Tropenmedizin und Internationale Gesundheit (DTG) (2017) Hinweise und Empfehlungen zu Reiseimpfungen, S\u00a01\u201339"},{"key":"852_CR9","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1007\/s00103-018-2807-y","volume":"61","author":"S Ehl","year":"2018","unstructured":"Ehl\u00a0S, Bogdan\u00a0C, Niehues\u00a0T et al (2018) Impfen bei Immundefizienz Anwendungshinweise zu den von der St\u00e4ndigen Impfkommission empfohlenen Impfungen. (II) Impfen bei 1. Prim\u00e4ren Immundefekterkrankungen und 2. HIV-Infektion. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 61:1034\u20131051","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"852_CR10","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1016\/j.mayocp.2019.02.025","volume":"94","author":"DO Freedman","year":"2019","unstructured":"Freedman\u00a0DO, Chen\u00a0LH (2019) Vaccines for international travel. Mayo Clin Proc 94:2314\u20132339","journal-title":"Mayo Clin Proc"},{"key":"852_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","volume":"79","author":"V Furer","year":"2020","unstructured":"Furer\u00a0V, Rondaan\u00a0C, Heijstek\u00a0MW et\u00a0al (2020) 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 79:39\u201352","journal-title":"Ann Rheum Dis"},{"key":"852_CR12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s11926-015-0519-y","volume":"17","author":"N Groot","year":"2015","unstructured":"Groot\u00a0N, Heijstek\u00a0MW, Wulffraat\u00a0NM (2015) Vaccinations in paediatric rheumatology: an update on current developments. Curr Rheumatol Rep 17:46","journal-title":"Curr Rheumatol Rep"},{"key":"852_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/tay018","author":"V Hall","year":"2018","unstructured":"Hall\u00a0V, Johnson\u00a0D, Torresi\u00a0J (2018) Travel and biologic therapy: travel-related infection risk, vaccine response and recommendations. J\u00a0Travel Med. https:\/\/doi.org\/10.1093\/jtm\/tay018","journal-title":"J Travel Med"},{"key":"852_CR14","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1136\/ard.2011.150193","volume":"70","author":"MW Heijstek","year":"2011","unstructured":"Heijstek\u00a0MW, Ott De Bruin\u00a0LM, Bijl\u00a0M et\u00a0al (2011) EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis 70:1704\u20131712","journal-title":"Ann Rheum Dis"},{"key":"852_CR15","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.vaccine.2015.12.029","volume":"34","author":"KB Hertzell","year":"2016","unstructured":"Hertzell\u00a0KB, Pauksens\u00a0K, Rombo\u00a0L et al (2016) Tick-borne encephalitis (TBE) vaccine to medically immunosuppressed patients with rheumatoid arthritis: A prospective, open-label, multi-centre study. Vaccine 34:650\u2013655","journal-title":"Vaccine"},{"key":"852_CR16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11926-015-0542-z","volume":"17","author":"G Horneff","year":"2015","unstructured":"Horneff\u00a0G (2015) Biologic-associated infections in pediatric rheumatology. Curr Rheumatol Rep 17:66","journal-title":"Curr Rheumatol Rep"},{"key":"852_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/jtm.12184","volume":"22","author":"VK Jaeger","year":"2015","unstructured":"Jaeger\u00a0VK, Ruegg\u00a0R, Steffen\u00a0R et al (2015) Travelers with immune-mediated inflammatory diseases: are they different? J\u00a0Travel Med 22:161\u2013167","journal-title":"J Travel Med"},{"key":"852_CR18","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s00108-018-0511-5","volume":"59","author":"T Jelinek","year":"2018","unstructured":"Jelinek\u00a0T (2018) What is verified for travel vaccinations? Internist 59:1255\u20131267","journal-title":"Internist"},{"key":"852_CR19","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00103-019-03067-w","volume":"63","author":"K Kling","year":"2020","unstructured":"Kling\u00a0K, Wichmann\u00a0O, Burchard\u00a0G (2020) Travel vaccinations for certain groups of persons. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 63:85\u201392","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"852_CR20","first-page":"290","volume":"29","author":"M Lahiri","year":"2015","unstructured":"Lahiri\u00a0M, Dixon\u00a0WG (2015) Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis. Best practice & research. Clin Rheumatol 29:290\u2013305","journal-title":"Clin Rheumatol"},{"key":"852_CR21","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1007\/s00103-017-2555-4","volume":"60","author":"T Niehues","year":"2017","unstructured":"Niehues\u00a0T, Bogdan\u00a0C, Hecht\u00a0J et\u00a0al (2017) Impfen bei Immundefizienz Anwendungshinweise zu den von der St\u00e4ndigen Impfkommission empfohlenen Impfungen (I) Grundlagenpapier. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 60:674\u2013684","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"852_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.tmaid.2017.12.004","volume":"21","author":"A Rosdahl","year":"2018","unstructured":"Rosdahl\u00a0A, Herzog\u00a0C, Frosner\u00a0G et al (2018) An extra priming dose of hepatitis A vaccine to adult patients with rheumatoid arthritis and drug induced immunosuppression\u2014A prospective, open-label, multi-center study. Travel Med Infect Dis 21:43\u201350","journal-title":"Travel Med Infect Dis"},{"key":"852_CR23","doi-asserted-by":"publisher","DOI":"10.1055\/a-0852-2732","author":"C Rothe","year":"2019","unstructured":"Rothe\u00a0C, Alberer\u00a0M, B\u00fchler\u00a0S et\u00a0al (2019) Reiseimpfungen-Hinweise und Empfehlungen des St\u00e4ndigen Ausschusses der Reisemedizin (StAR) der DTG. Flug Reisemed. https:\/\/doi.org\/10.1055\/a-0852-2732","journal-title":"Flug Reisemed"},{"issue":"2020","key":"852_CR24","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s00103-019-03064-z","volume":"63","author":"C Rothe","year":"2020","unstructured":"Rothe\u00a0C, Boecken\u00a0G, St\u00e4ndiger Ausschuss Reisemedizin (StAR) der Deutschen Gesellschaft f\u00fcr Tropenmedizin und Globale Gesundheit (DTG) (2020) Travel vaccinations. Bundesgesundheitsblatt 63(2020):74\u201384","journal-title":"Bundesgesundheitsblatt"},{"key":"852_CR25","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1093\/cid\/cit684","volume":"58","author":"LG Rubin","year":"2014","unstructured":"Rubin\u00a0LG, Levin\u00a0MJ, Ljungman\u00a0P et\u00a0al (2014) 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 58:e44\u2013e100","journal-title":"Clin Infect Dis"},{"key":"852_CR26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1055\/s-0037-1618353","volume":"35","author":"F Speth","year":"2015","unstructured":"Speth\u00a0F, Minden\u00a0K (2015) Impfungen bei Kindern und Jugendlichen mit rheumatischen und muskuloskelettalen Erkrankungen. Arthritis Rheuma 35:44\u201355","journal-title":"Arthritis Rheuma"},{"key":"852_CR27","first-page":"313","volume":"34","author":"St\u00e4ndige Impfkommission","year":"2019","unstructured":"St\u00e4ndige Impfkommission (2019) Empfehlungen der St\u00e4ndigen Impfkommission (STIKO) am Robert Koch-Institut. Epid Bull 34:313\u2013364","journal-title":"Epid Bull"},{"key":"852_CR28","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/jtm.12050","volume":"20","author":"W Van Den Bijllaardt","year":"2013","unstructured":"Van Den Bijllaardt\u00a0W, Siers\u00a0HM, Timmerman-Kok\u00a0C et al (2013) Seroprotection after hepatitis a\u00a0vaccination in patients with drug-induced immunosuppression. J\u00a0Travel Med 20:278\u2013282","journal-title":"J Travel Med"},{"key":"852_CR29","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s00103-019-02905-1","volume":"62","author":"N Wagner","year":"2019","unstructured":"Wagner\u00a0N, Assmus\u00a0F, Arendt\u00a0G et al (2019) Impfen bei Immundefizienz Anwendungshinweise zu den von der St\u00e4ndigen Impfkommission empfohlenen Impfungen. (IV) Impfen bei Autoimmunkrankheiten, bei anderen chronisch-entz\u00fcndlichen Erkrankungen und unter immunmodulatorischer Therapie. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 62:494\u2013515","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"issue":"Suppl 4","key":"852_CR30","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00508-016-1033-6","volume":"128","author":"U Wiedermann","year":"2016","unstructured":"Wiedermann\u00a0U, Sitte\u00a0HH, Burgmann\u00a0H et\u00a0al (2016) Guidelines for vaccination of immunocompromised individuals. Wien Klin Wochenschr 128(Suppl 4):337\u2013376","journal-title":"Wien Klin Wochenschr"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-020-00852-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-020-00852-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-020-00852-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T23:30:07Z","timestamp":1629934207000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-020-00852-w"}},"subtitle":["Besonderheiten bei Kindern und Erwachsenen","Specific considerations in children and adults"],"short-title":[],"issued":{"date-parts":[[2020,8,26]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["852"],"URL":"https:\/\/doi.org\/10.1007\/s00393-020-00852-w","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,26]]},"assertion":[{"value":"26 August 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"U.\u00a0Heininger hat Honorare f\u00fcr Vortr\u00e4ge zu Impfthemen ohne Produktbezug von MSD, Pfizer, und Sanofi erhalten. T.\u00a0Welzel und A.\u00a0W\u00f6rner erkl\u00e4ren, keine finanziellen oder pers\u00f6nlichen Beziehungen zu Dritten zu haben, deren Interesse den Beitragsinhalt positiv oder negativ beeinflusst haben k\u00f6nnte. Es besteht kein Interessenkonflikt.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag basiert auf bereits publizierter Literatur. Der Beitrag enth\u00e4lt keine neuen eigenen Studienergebnisse aus Forschung am Menschen oder an Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}